Buprenorphine/Naloxone-Facilitated Rehabilitation for Opioid Dependent Adolescents/Young Adults

George Woody, MD
Lead Investigator
Department of Psychiatry
University of Pennsylvania

The usual treatment for opioid-addicted youth is detoxification and counseling.  Some treatment providers are reluctant to use opioid agonist medications in this population, especially for long-term opioid maintenance.  This study compared Bup/Nx treatment for 9 weeks and taper for 3 weeks to treatment as usual (Bup/Nx detox for 2 weeks).  Both arms received counseling for 12 weeks.
CTN-0010 Study Protocol


Results of the study showed that continuing Bup/Nx for 12 weeks vs. 2 weeks improved outcomes.  During weeks 1 through 12, patients in the 12-week Bup/Nx group reported less opioid use (P<.001), better retention (70% vs. 21%; p<.0001), less injecting (P=.01), and less use of cocaine (p<.001) and marijuana (p<.001).  Continuing treatment with Bup/Nx for 12 weeks appears to be safe in opioid addicted adolescents and young adults.

Primary Outcomes Article: Woody G, et al. Extended vs. short-term buprenorphine/naloxone for treatment of opioid-addicted youth: A randomized trial. Journal of the American Medical Association 2008;300(17):2003-2011. [get article]


Publications about CTN-0010

Study data from NIDA Data Share

Blending Team Product: Buprenorphine Treatment for Young Adults
Blending Team Product: Buprenorphine Suite (NCT00078130)

NIDA protocol page

Delaware Valley (Lead) search www
Mid-Atlantic search www
Mountain Manor Treatment Programs search
New England Consortium search www
(formerly Northern New England) search www
Mercy Hospital search
North Carolina search www
Duke Addictions Program search
Southwest search www
Addiction and Substance Abuse Program (ASAP) search

Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 4/2012 --